MedTrace Logo

H1N1 Vaccine Safety in Manitoba, Canada

NCT01421251 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800000

Last updated 2012-09-12

No results posted yet for this study

Summary

Many people worldwide received the monovalent adjuvanted H1N1 vaccine. However, very little is known about the safety of the vaccine, particularly beyond the first few weeks after vaccination. This study will combine data from a well-established immunization registry in Manitoba with data from hospitalization and physician records, to examine the safety of the vaccine in the six month period post-vaccination. Studies on vaccine safety are important as the public's perception of the safety of a vaccine has a major role in its uptake.

Conditions

  • H1N1 Influenza

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • International Centre for Infectious Diseases, Canada

    lead OTHER

Principal Investigators

  • Salah Mahmud, M.D., Ph.D. · University of Manitoba

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01421251 on ClinicalTrials.gov